Reported use of data monitoring committees in the main published reports of randomized controlled trials: a cross-sectional study

Abstract

Background We describe a review of published main reports of randomized controlled trials (RCTs), in order to measure the frequency of reported use of data monitoring committees (DMCs) and factors associated with reported DMC use. Methods Twenty-four higher impact general and specialist medical journals were handsearched for main reports of RCTs in order to provide a cross-sectional sample of trials published in the year 2000. Additionally, the same general medical journals were handsearched for 1990 to allow a comparison across time.

Results Of 662 RCTs published in 2000, 120 (18%) explicitly reported using a DMC, while 107 (16%) reported planned interim analyses. Overall, about a quarter (24%) reported at least one of these. A higher proportion of trials reported using a DMC in 2000 than 1990 (70/282, 25% versus 21/204, 10%) in the general medical journals. Logistic regression models suggested the more important variables associated with increased reported DMC use were: later year of publication, publication in general medical journal, survival-based endpoint, multicentre trial, increasing number of patients recruited, at least one arm involving a placebo, at least one arm involving a drug, factorial design and USA involvement in the trial.

Conclusions In 2000, about a quarter of main RCT reports mention use of a DMC. Actual use of DMCs is likely to be somewhat greater. Reporting use of a DMC was more likely for larger and longer trials among other factors. We believe the factors affecting reported use affect actual use. It is recommended that when a DMC oversees a trial, brief details should be explicitly included in the main trial paper. Standard nomenclature for DMCs is recommended.

Get full access to this article

View all access options for this article.

References

Freidlin B , Korn EL , George SL . Data monitoring committees and interim monitoring guidelines. Control Clin Trials 1999; 20(5): 395–407.

Pocock SJ . Statistical and ethical issues in monitoring clinical trials. Stat Med 1993; 12(15–16): 1459–1469.

Fleming TR , DeMets DL . Monitoring of clinical trials: issues and recommendations. Control Clin Trials 1993; 14(3): 183–197.

Medical Research Council (MRC) . MRC guidelines for good clinical practice. London, UK: Medical Research Council Publications Department, 1998.

Wittes J . Behind closed doors: the data monitoring board in randomized clinical trials. Stat Med 1993; 12(5 –6): 419–424.

Damocles Group . Issues in data monitoring and interim analysis of trials (DAMOCLES project). London: Health Technology Assessment, 2003.

ISI, Inc. Journal Citation Reports, 1999 science edition. Philadelphia (PA): Institute for Scientific Information, Inc., 2000.

Cairns JA , Hallstrom A , Held P . Should all trials have a data safety and monitoring committee? Am Heart J 2001; 141(1): 156–163.

O'Neill RT . Conclusions. 2. Stat Med 1994; 13(13 –14): 1493–1499.

10.

O'Brien PC , Fleming TR . Testing procedure for clinical trials. Biometrics 1979; 35: 549–556.

11.

Begg C , Cho M , Eastwood S , et al. Improving the quality of reporting of randomised controlled trials. The CONSORT statement. JAMA 1996; 276(8): 637–639.

12.

Meinert CL , Tonascia S . Clinical trials: design, conduct and analysis. New York: Oxford University Press, 1986.

13.

ICH Steering Committee . ICH harmonised tripartite guideline: Statistical principles for clinical trials (E9). http://www.ich.org/pdfICH/e9.pdf. Last accessed 2 August 2002.

14.

Sydes MR , Spiegelhalter DJ , Altman DG , Babiker AB , Parmar MKB , and the DAMOCLES Group . Review of the literature on Data Monitoring Committees for randomised controlled trials. Clin Trials 2004, 1: 60–79.

15.

Ellenberg S , Fleming T , DeMets D . Data monitoring committees in clinical trials: a practical perspective. Chichester: John Wiley and Sons Ltd, 2002.